Goldman Sachs
STML

Goldman Sachs’s Stemline Therapeutics, Inc. STML Stock Holding History

Goldman Sachs’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50,000
Closed -$555K – 6823
2017
Q3 		$555K Buy
+50,000
New +$470K ﹤0.01% 5022

Goldman Sachs's STML Position: Q2 2020 in Review

Goldman Sachs sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 1,905,276 shares — an estimated $9.22M sold.

Goldman Sachs first reported a position in STML in Q2 2013 and held it in 23 quarters. The position peaked at $22.6M in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

  • Goldman Sachs reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Goldman Sachs sold 1,905,276 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $9.22M.
  • Goldman Sachs first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 23 quarters.
  • Goldman Sachs's Stemline Therapeutics, Inc. position peaked at $22.6M in Q2 2019.
  • 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Goldman Sachs's 13F filing for Q2 2020, filed 12 Aug 2020.